Skip to search formSkip to main contentSkip to account menu

CPI203

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AcetamidesAzepines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 2161: Pharmacological downregulation of BFL-1 by the BET bromodomain inhibitor CPI203 overcomes ABT-199 resistance inMYC+/BCL2+double hit lymphoma
Double-hit lymphoma (DHL) is a rare subtype of B-cell lymphoma characterized by MYC and either BCL2 or BCL6 chromosomal… 
Highly Cited
2014
Highly Cited
2014
The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
Endogenous c-MYC (MYC) has been reported to be a potential pharmacological target to trigger ubiquitous tumor regression of… 
2014
2014
Abstract 1691: Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Mantle cell lymphoma (MCL) is an aggressive B lymphoid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)